These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 21729174)

  • 1. Experimental testing of skin reactions to insulin detemir in diabetes patients naïve to insulin detemir.
    O'goshi K; Serup J; Blaaholm B; Thomsen HK; Rossing P; Tarnow L
    Skin Res Technol; 2011 Nov; 17(4):411-9. PubMed ID: 21729174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin detemir: new drug. A second long-acting insulin analogue: many uncertainties, few advantages.
    Prescrire Int; 2006 Oct; 15(85):163-7. PubMed ID: 17121210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Injection of acidic or neutral insulin and pain: a single-center, prospective, controlled, noninterventional study in pediatric patients with type 1 diabetes mellitus.
    Karges B; Muche R; Riegger I; Moritz M; Heinze E; Debatin KM; Wabitsch M; Karges W
    Clin Ther; 2006 Dec; 28(12):2094-101. PubMed ID: 17296465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weak allergenicity of recombinant hirudin CGP 39393 (REVASC) in immunocompetent volunteers. The European Hirudin in Thrombosis Group (HIT Group).
    Close P; Bichler J; Kerry R; Ekman S; Bueller HR; Kienast J; Marbet GA; Schramm W; Verstraete M
    Coron Artery Dis; 1994 Nov; 5(11):943-9. PubMed ID: 7719527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-acting insulin allergy in a diabetic child.
    Mastrorilli C; Rizzuti L; Cangelosi AM; Iovane B; Chiari G; Caffarelli C
    Int J Immunopathol Pharmacol; 2017 Jun; 30(2):174-177. PubMed ID: 28368217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin detemir (levemir), a new long-acting insulin.
    Med Lett Drugs Ther; 2006 Jul; 48(1238):54-5. PubMed ID: 16841022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin degludec. Uncertainty over cardiovascular harms.
    Prescrire Int; 2014 Jun; 23(150):149. PubMed ID: 25121146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe insulin allergy after percutaneous transluminal coronary angioplasty.
    Wang C; Ding ZY; Shu SQ; Liu Y; Chen YC; Ran XW; An ZM; Tian HM; Tong NW; Li XJ; Yu YR
    Clin Ther; 2009 Mar; 31(3):569-74. PubMed ID: 19393846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoglycemia rates with basal insulin analogs.
    Little S; Shaw J; Home P
    Diabetes Technol Ther; 2011 Jun; 13 Suppl 1():S53-64. PubMed ID: 21668338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Delayed hypersensitivity to protamine and immediate hypersensitivity to insulin].
    Köllner A; Senff H; Engelmann L; Kalveram KJ; Velcovsky HG; Haneke E
    Dtsch Med Wochenschr; 1991 Aug; 116(33):1234-8. PubMed ID: 1831420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort.
    Dornhorst A; Lüddeke HJ; Sreenan S; Koenen C; Hansen JB; Tsur A; Landstedt-Hallin L
    Int J Clin Pract; 2007 Mar; 61(3):523-8. PubMed ID: 17313628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does insulin detemir have a role in reducing risk of insulin-associated weight gain?
    Hermansen K; Davies M
    Diabetes Obes Metab; 2007 May; 9(3):209-17. PubMed ID: 17391147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin allergy.
    Ghazavi MK; Johnston GA
    Clin Dermatol; 2011; 29(3):300-5. PubMed ID: 21496738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study.
    Porcellati F; Rossetti P; Busciantella NR; Marzotti S; Lucidi P; Luzio S; Owens DR; Bolli GB; Fanelli CG
    Diabetes Care; 2007 Oct; 30(10):2447-52. PubMed ID: 17623819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma glucose and hypoglycaemia following exercise in people with Type 1 diabetes: a comparison of three basal insulins.
    Arutchelvam V; Heise T; Dellweg S; Elbroend B; Minns I; Home PD
    Diabet Med; 2009 Oct; 26(10):1027-32. PubMed ID: 19900235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved glycaemic control with no weight gain: a 26-week, open label, non-randomised, non-interventional observational study on type 2 diabetes subjects using insulin detemir.
    Tripathi S; Chandalia HB; Rao PV; Badgandi M; Patni R; Subbanna PK; Shetty R; Kumar H
    J Indian Med Assoc; 2011 Apr; 109(4):275-8. PubMed ID: 22187803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.
    Haak T; Tiengo A; Draeger E; Suntum M; Waldhäusl W
    Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir.
    Peterson GE
    Curr Med Res Opin; 2006 Dec; 22(12):2613-9. PubMed ID: 17166343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization.
    Cooke CE; Lee HY; Tong YP; Haines ST
    Curr Med Res Opin; 2010 Jan; 26(1):231-8. PubMed ID: 19921965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study.
    Dornhorst A; Lüddeke HJ; Sreenan S; Kozlovski P; Hansen JB; Looij BJ; Meneghini L;
    Int J Clin Pract; 2008 Apr; 62(4):659-65. PubMed ID: 18324957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.